Zydus Lifesciences gains on getting USFDA`s final nod for Isotretinoin capsules
Zydus Lifesciences is currently trading at Rs. 919.15, up by 11.15 points or 1.23% from its previous closing of Rs. 908.00 on the BSE.
The scrip opened at Rs. 911.85 and has touched a high and low of Rs. 921.00 and Rs. 911.40 respectively. So far 17923 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 921.00 and Rs. 866.55 respectively. The current market cap of the company is Rs. 92513.15 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Isotretinoin capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg (USRLD: Absorica Capsules, 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg).
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne. Isotretinoin capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad. Isotretinoin capsules had annual sales of $115.4 million in the United States (IQVIA MAT March 2025). The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
